Imperial College London

Professor Hashim Ahmed

Faculty of MedicineDepartment of Surgery & Cancer

Chair in Urology (Clinical)
 
 
 
//

Contact

 

hashim.ahmed

 
 
//

Location

 

5L28Lab BlockCharing Cross Campus

//

Summary

 

Publications

Publication Type
Year
to

270 results found

Faria R, Soares M, Spackman E, Ahmed H, Brown L, Rs K, Emberton M, Sculpher Met al., 2017, COST-EFFECTIVENESS OF DIAGNOSIS: FROM TESTS TO LONG-TERM OUTCOMES AND COSTS, Publisher: ELSEVIER SCIENCE INC, Pages: A405-A406, ISSN: 1098-3015

CONFERENCE PAPER

Georgiou PS, Jaros J, Payne H, Allen C, Shah TT, Ahmed HU, Gibson E, Barratt D, Treeby BEet al., 2017, Beam distortion due to gold fiducial markers during salvage high-intensity focused ultrasound in the prostate, MEDICAL PHYSICS, Vol: 44, Pages: 679-693, ISSN: 0094-2405

JOURNAL ARTICLE

Grey ADR, Ahmed HU, 2017, Re: Limitations of Elastography Based Prostate Biopsy, JOURNAL OF UROLOGY, Vol: 197, Pages: 263-264, ISSN: 0022-5347

JOURNAL ARTICLE

Hindley RG, Mistry K, Ahmed HU, 2017, The PROMIS of a New Diagnostic Pathway for Men with Suspected Prostate Cancer., Clin Oncol (R Coll Radiol), Vol: 29, Pages: 397-400

JOURNAL ARTICLE

Hu Y, Kasivisvanathan V, Simmons LAM, Clarkson MJ, Thompson SA, Shah TT, Ahmed HU, Punwani S, Hawkes DJ, Emberton M, Moore CM, Barratt DCet al., 2017, Development and Phantom Validation of a 3-D-Ultrasound-Guided System for Targeting MRI-Visible Lesions During Transrectal Prostate Biopsy, IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING, Vol: 64, Pages: 946-958, ISSN: 0018-9294

JOURNAL ARTICLE

Kanthabalan A, Peters M, Van Vulpen M, McCartan N, Hindley RG, Emara A, Moore CM, Arya M, Emberton M, Ahmed HUet al., 2017, Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer, BJU INTERNATIONAL, Vol: 120, Pages: 246-256, ISSN: 1464-4096

JOURNAL ARTICLE

Linch M, Goh G, Hiley C, Shanmugabavan Y, McGranahan N, Rowan A, Wong YNS, King H, Furness A, Freeman A, Linares J, Akarca A, Herrero J, Rosenthal R, Harder N, Schmidt G, Wilson GA, Birkbak NJ, Mitter R, Dentro S, Cathcart P, Arya M, Johnston E, Scott R, Hung M, Emberton M, Attard G, Szallasi Z, Punwani S, Quezada SA, Marafioti T, Gerlinger M, Ahmed HU, Swanton Cet al., 2017, Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters, ANNALS OF ONCOLOGY, Vol: 28, Pages: 2472-2480, ISSN: 0923-7534

JOURNAL ARTICLE

MacLennan S, Williamson PR, Bekema H, Campbell M, Ramsay C, N'Dow J, MacLennan S, Vale L, Dahm P, Mottet N, Lam T, COMPACTERS Study Groupet al., 2017, A core outcome set for localised prostate cancer effectiveness trials., BJU Int, Vol: 120, Pages: E64-E79

OBJECTIVE: To develop a core outcome set (COS) applicable for effectiveness trials of all interventions for localised prostate cancer. Many treatments exist for localised prostate cancer, although it is unclear which offers the optimal therapeutic ratio; which is confounded by inconsistencies in the selection, definition, measurement and reporting of outcomes in clinical trials. PATIENTS, SUBJECTS AND METHODS: A list of 79 outcomes was derived from a systematic review of published localised prostate cancer effectiveness studies and semi-structured interviews with 15 patients with prostate cancer patients. A two-stage consensus process involving 118 patients and 56 international healthcare professionals (HCPs; cancer specialist nurses, urological surgeons and oncologists) was undertaken, consisting of a three-round Delphi survey followed by a face-to-face consensus panel meeting of 13 HCPs and eight patients. RESULTS: The final COS included 19 outcomes. In all, 12 apply to all interventions: death from prostate cancer, death from any cause, local disease recurrence, distant disease recurrence/metastases, disease progression, need for salvage therapy, overall quality of life, stress urinary incontinence, urinary function, bowel function, faecal incontinence, and sexual function. Seven were intervention-specific: perioperative deaths (surgery), positive surgical margin (surgery), thromboembolic disease (surgery), bothersome or symptomatic urethral or anastomotic stricture (surgery), need for curative treatment (active surveillance), treatment failure (ablative therapy), and side-effects of hormonal therapy (hormone therapy). The UK-centric participants may limit the generalisability to other countries, but trialists should reason why the COS would not be applicable. The default position should not be that a COS developed in one country will automatically not be applicable elsewhere. CONCLUSION: We have established a COS for trials of effectiveness in localised prostate

JOURNAL ARTICLE

Miah S, Ahmed HU, 2017, The death of ink: the value of typing skills as an addition to the medical school curriculum, ADVANCES IN MEDICAL EDUCATION AND PRACTICE, Vol: 8, Pages: 701-702, ISSN: 1179-7258

JOURNAL ARTICLE

Moore CM, Robertson NL, Jichi F, Damola A, Ambler G, Giganti F, Ridout AJ, Bott SRJ, Winkler M, Ahmed HU, Arya M, Mitra AV, McCartan N, Freeman A, Jameson C, Castro R, Gambarota G, Whitcher BJ, Allen C, Kirkham A, Emberton Met al., 2017, The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPED-A Randomized, Placebo Controlled, Double-Blind Clinical Trial, JOURNAL OF UROLOGY, Vol: 197, Pages: 1006-1013, ISSN: 0022-5347

JOURNAL ARTICLE

Segaran SV, Emara AM, Mahesan T, Silverman J, Ahmed HU, Bott SRJ, Hindley RGet al., 2017, The ability of free to total prostate-specific antigen and prostate-specific antigen density to detect clinically significant prostate cancer in men undergoing transperineal template biopsy, JOURNAL OF CLINICAL UROLOGY, Vol: 10, Pages: 529-534, ISSN: 2051-4158

JOURNAL ARTICLE

Shah TT, To WKL, Ahmed HU, 2017, Magnetic resonance imaging in the early detection of prostate cancer and review of the literature on magnetic resonance imaging-stratified clinical pathways, EXPERT REVIEW OF ANTICANCER THERAPY, Vol: 17, Pages: 1159-1168, ISSN: 1473-7140

JOURNAL ARTICLE

Sidhu HS, Benigno S, Ganeshan B, Dikaios N, Johnston EW, Allen C, Kirkham A, Groves AM, Ahmed HU, Emberton M, Taylor SA, Halligan S, Punwani Set al., 2017, "Textural analysis of multiparametric MRI detects transition zone prostate cancer", EUROPEAN RADIOLOGY, Vol: 27, Pages: 2348-2358, ISSN: 0938-7994

JOURNAL ARTICLE

Simmons LAM, Kanthabalan A, Arya M, Briggs T, Barratt D, Charman SC, Freeman A, Gelister J, Hawkes D, Hu Y, Jameson C, McCartan N, Moore CM, Punwani S, Ramachandran N, van der Meulen J, Emberton M, Ahmed HUet al., 2017, The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy, BRITISH JOURNAL OF CANCER, Vol: 116, Pages: 1159-1165, ISSN: 0007-0920

JOURNAL ARTICLE

Tay KJ, Scheltema MJ, Ahmed HU, Barret E, Coleman JA, Dominguez-Escrig J, Ghai S, Huang J, Jones JS, Klotz LH, Robertson CN, Sanchez-Salas R, Scionti S, Sivaraman A, de la Rosette J, Polascik TJet al., 2017, Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project, PROSTATE CANCER AND PROSTATIC DISEASES, Vol: 20, Pages: 294-299, ISSN: 1365-7852

JOURNAL ARTICLE

Valerio M, Dickinson L, Ali A, Ramachadran N, Donaldson I, Mccartan N, Freeman A, Ahmed HU, Emberton Met al., 2017, Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer, JOURNAL OF UROLOGY, Vol: 197, Pages: 647-653, ISSN: 0022-5347

JOURNAL ARTICLE

Valerio M, Shah TT, Shah P, Mccartan N, Emberton M, Arya M, Ahmed HUet al., 2017, Magnetic resonance imaging-transrectal ultrasound fusion focal cryotherapy of the prostate: A prospective development study, UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, Vol: 35, ISSN: 1078-1439

JOURNAL ARTICLE

Ahmed H, Emberton M, 2016, Histopathological Outcomes after Irreversible Electroporation for Prostate Cancer: Results of an Ablate and Resect Study COMMENT, JOURNAL OF UROLOGY, Vol: 196, Pages: 559-559, ISSN: 0022-5347

JOURNAL ARTICLE

Ahmed HU, 2016, Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial EDITORIAL COMMENT, JOURNAL OF UROLOGY, Vol: 196, Pages: 74-75, ISSN: 0022-5347

JOURNAL ARTICLE

Ahmed HU, 2016, The PROMIS of MRI, BJU INTERNATIONAL, Vol: 118, Pages: 7-7, ISSN: 1464-4096

JOURNAL ARTICLE

Bass EJ, Ahmed HU, 2016, Focal therapy in prostate cancer: A review of seven common controversies, CANCER TREATMENT REVIEWS, Vol: 51, Pages: 27-34, ISSN: 0305-7372

JOURNAL ARTICLE

Bosaily AE-S, Valerio M, Hu Y, Freeman A, Jameson C, Brown L, Kaplan R, Hindley RG, Barratt D, Emberton M, Ahmed HUet al., 2016, The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial, PROSTATE CANCER AND PROSTATIC DISEASES, Vol: 19, Pages: 258-263, ISSN: 1365-7852

JOURNAL ARTICLE

Dickinson L, Arya M, Afzal N, Cathcart P, Charman SC, Cornaby A, Hindley RG, Lewi H, McCartan N, Moore CM, Nathan S, Ogden C, Persad R, van der Meulen J, Weir S, Emberton M, Ahmed HUet al., 2016, Medium- term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort, EUROPEAN UROLOGY, Vol: 70, Pages: 668-674, ISSN: 0302-2838

JOURNAL ARTICLE

Grey A, Ahmed HU, 2016, Multiparametric ultrasound in the diagnosis of prostate cancer, CURRENT OPINION IN UROLOGY, Vol: 26, Pages: 114-119, ISSN: 0963-0643

JOURNAL ARTICLE

Hamid S, Guillaumier S, Shah T, Arya M, Ahmed HUet al., 2016, PROSTATE CANCER RECURRENCE AFTER FOCAL THERAPY: TREATMENT OPTIONS, ARCHIVOS ESPANOLES DE UROLOGIA, Vol: 69, Pages: 375-383, ISSN: 0004-0614

JOURNAL ARTICLE

Haroon A, Ahmed HU, Cathcart P, Almuhaideb A, Kayani I, Dickson J, Kirkham A, Freeman A, Emberton M, Bomanji Jet al., 2016, 18F-FECH PET/CT to Assess Clinically Significant Disease in Prostate Cancer: Correlation With Maximum and Total Cancer Core Length Obtained via MRI-Guided Template Mapping Biopsies., AJR Am J Roentgenol, Vol: 207, Pages: 1297-1306

OBJECTIVE: The objective of this study was to detect clinically significant and insignificant prostate cancer on 18F-fluoroethylcholine (FECH) PET/CT and to correlate findings with transperineal template-guided prostate mapping (TPM) biopsy. SUBJECTS AND METHODS: Fifty-six lobes of the prostate were analyzed in 28 men who underwent FECH PET/CT and TPM. Whole-body images and pelvic images were acquired at 60 and 90 minutes after tracer administration. FECH PET/CT findings were correlated with TPM. Sensitivity, specificity, positive predictive values, negative predictive values, and AUC of dual phase FECH PET/CT were calculated. RESULTS: Mean age of the patients was 68.8 years (range, 53-79 years), and mean prostate-specific antigen level was 12.1 ng/mL (range, 0.6-45 ng/mL). Mean maximum cancer core length was 4.4 mm (median, 4 mm; range, 1-14 mm) and mean total cancer core length, 14.6 mm (median, 14.6 mm; range, 1-82 mm). Prostate cancer was identified in 38 lobes with a Gleason score of 6 in five lobes (13%), 7 in 27 lobes (71%), 8 in four lobes (11%), and 9 in two lobes (5%). FECH PET/CT showed findings of prostate cancer in 46/56 lobes (82%). The ranges for maximum standardized uptake value for 60- and 90-minute FECH PET/CT were 1.3-11.4 and 1.2-10.9, respectively. Clinically significant cancer was seen in 30 of 38 positive lobes; eight had clinically insignificant disease. For 60-minute imaging, the sensitivity, specificity, and ROC AUC were 75%, 75%, and 0.746 (95% CI, 0.612-0.853). For 90-minute imaging, the sensitivity, specificity, and ROC AUC were 73.7%, 58.3%, and 0.646 (95% CI, 0.498-0.776). Overall sensitivity, specificity, positive predictive value, and negative predictive value were 95%, 50%, 82.6%, and 80%, respectively. CONCLUSION: FECH PET/CT can detect prostate cancer and localizes TPM biopsy-proven clinically significant prostate cancer with sensitivity of greater than 89.7%. Of the two imaging durations, 60-minute imaging is more sensitive and s

JOURNAL ARTICLE

Jarow JP, Ahmed HU, Choyke PL, Taneja SS, Scardino PTet al., 2016, Partial Gland Ablation for Prostate Cancer: Report of a Food and Drug Administration, American Urological Association, and Society of Urologic Oncology Public Workshop, UROLOGY, Vol: 88, Pages: 8-13, ISSN: 0090-4295

JOURNAL ARTICLE

Johnston E, Pye H, Bonet-Carne E, Panagiotaki E, Patel D, Galazi M, Heavey S, Carmona L, Freeman A, Trevisan G, Allen C, Kirkham A, Burling K, Stevens N, Hawkes D, Emberton M, Moore C, Ahmed HU, Atkinson D, Rodriguez-Justo M, Ng T, Alexander D, Whitaker H, Punwani Set al., 2016, INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer, BMC CANCER, Vol: 16, ISSN: 1471-2407

JOURNAL ARTICLE

Kanthabalan A, Abd-Alazeez M, Arya M, Allen C, Freeman A, Jameson C, Kirkham A, Mitra AV, Payne H, Punwani S, Ramachandran N, Walkden M, Emberton M, Ahmed HUet al., 2016, Transperineal Magnetic Resonance Imaging-targeted Biopsy versus Transperineal Template Prostate Mapping Biopsy in the Detection of Localised Radio-recurrent Prostate Cancer, CLINICAL ONCOLOGY, Vol: 28, Pages: 568-576, ISSN: 0936-6555

JOURNAL ARTICLE

Miah S, Ahmed HU, Freeman A, Emberton Met al., 2016, Does true Gleason pattern 3 merit its cancer descriptor?, NATURE REVIEWS UROLOGY, Vol: 13, Pages: 541-548, ISSN: 1759-4812

JOURNAL ARTICLE

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: id=00936994&limit=30&person=true&page=2&respub-action=search.html